Theravance Biopharma Inc (0TB)

Francoforte
Valuta in EUR
8,9000
+0,2000(+2,30%)
Dati in Ritardo

Conto Economico 0TB

Conto economico avanzato
Fine Periodo:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Totale fatturato
aa.aaaa.aaaa.aaaa.aaaa.aa73,4171,8655,3151,3557,42
Totale crescita fatturato
aa.aaaa.aaaa.aaaa.aaaa.aa+21,61%-2,12%-23,03%-7,17%+11,84%
Costo del venduto
aa.aaaa.aaaa.aaaa.aaaa.aa219,25260,95193,6663,3940,62
Utile Lordo
aa.aaaa.aaaa.aaaa.aaaa.aa-145,83-189,1-138,35-12,0516,8
Crescita utile lordo
aa.aaaa.aaaa.aaaa.aaaa.aa-2,92%-29,67%+26,84%+91,29%+239,49%
Margine profitti lordi
aa.aaaa.aaaa.aaaa.aaaa.aa-198,65%-263,16%-250,12%-23,46%29,26%
Altre spese operative, totale
aa.aaaa.aaaa.aaaa.aaaa.aa106,08108,5399,367,0770,1
Altre spese operative, crescita totale
Spese per Ricerca e Sviluppo
Vendite, Spese generali ed amministrative
Altre spese operative
Reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-251,92-297,63-237,64-79,12-53,29
Crescita reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-5,51%-18,15%+20,15%+66,71%+32,64%
Margine % EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa-343,14%-414,19%-429,65%-154,09%-92,8%
Spesa netta per interessi
aa.aaaa.aaaa.aaaa.aaaa.aa-23,67-3,81-6,540,376,71
Crescita spesa netta per interessi
aa.aaaa.aaaa.aaaa.aaaa.aa-417,65%+83,92%-71,78%+105,61%+1.727,25%
Spesa per interessi, totale
aa.aaaa.aaaa.aaaa.aaaa.aa-31,86-8,55-8,55-6,37-2,35
Reddito da interessi e investimenti
aa.aaaa.aaaa.aaaa.aaaa.aa8,24,742,016,749,06
Altre spese non operative, totale
aa.aaaa.aaaa.aaaa.aaaa.aa33,91-1,91-0,9-0,90,06
EBT escluse voci inusuali
aa.aaaa.aaaa.aaaa.aaaa.aa-241,68-303,34-245,08-79,65-46,53
Guadagno (Perdita) sulla vendita degli asset
aa.aaaa.aaaa.aaaa.aaaa.aa---2,71-
Altre voci inusuali, totale
aa.aaaa.aaaa.aaaa.aaaa.aa----3,03-
EBT, comprese voci insolite
aa.aaaa.aaaa.aaaa.aaaa.aa-241,68-303,34-265,22-92,82-49,27
Crescita EBT, comprese voci inusuali
aa.aaaa.aaaa.aaaa.aaaa.aa-6,9%-25,52%+12,57%+65%+46,92%
EBT, compreso margine voci inusuali
aa.aaaa.aaaa.aaaa.aaaa.aa-329,2%-422,15%-479,51%-180,76%-85,8%
Tasse sui redditi
aa.aaaa.aaaa.aaaa.aaaa.aa-5,22-8,52-0,150,015,92
Reddito netto società
aa.aaaa.aaaa.aaaa.aaaa.aa-236,46-278,02-199,43872,13-55,19
Interessi di minoranza
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Reddito netto
aa.aaaa.aaaa.aaaa.aaaa.aa-236,46-278,02-199,43872,13-55,19
Crescita reddito netto
aa.aaaa.aaaa.aaaa.aaaa.aa-9,71%-17,58%+28,27%+537,32%-106,33%
Margine % reddito netto
aa.aaaa.aaaa.aaaa.aaaa.aa-322,08%-386,9%-360,55%1.698,54%-96,11%
Dividendo privilegiati e altri adeguamenti
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Utile netto comune escluse voci extra
aa.aaaa.aaaa.aaaa.aaaa.aa-236,46-294,82-265,07-92,82-55,19
EPS base - reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-4,25-4,73-3,82-1,26-1
EPS base - crescita reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-6,47%-11,22%+19,3%+66,95%+20,88%
EPS diluiti - reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-4,25-4,73-3,82-1,26-1
EPS diluiti - crescita reddito operativo
aa.aaaa.aaaa.aaaa.aaaa.aa-6,47%-11,24%+19,24%+66,98%+20,88%
Base azioni medie ponderate in circolazione
aa.aaaa.aaaa.aaaa.aaaa.aa55,6162,3569,4673,5955,3
Azioni medie ponderate diluite in circolazione
aa.aaaa.aaaa.aaaa.aaaa.aa55,6162,3569,4673,5955,3
Dividendo per azione
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Crescita dividendo per azione
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-248,93-294-232,83-76,08-53,19
Crescita EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-5,66%-18,11%+20,81%+67,32%+30,09%
Margine % EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-339,07%-409,14%-420,95%-148,18%-92,62%
EBIT
aa.aa